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Abstract 
Objectives: The detrimental haemodynamic changes observed in septicaemia are generalised vasodilation, arterial hypotension, and 
hyporesponsiveness to vasopressor compounds, all of which could he explained by the release of an endogenous vasodilator. 
Experimental and clinical evidence suggests that tumour necrosis factor-a (TNF) induces the expression of vascular nitric oxide (NO) 
synthase within hours and that NO released from smooth muscle cells could he involved in the pathogenesis of septic shock. The aim of 
this study was to investigate the role of NO in the vascular effects of TNF. Methods: Using the dorsal hand vein compliance technique, 
the effect of the NO synthase inhibitor L-NG-monomethyl-arginine (L-NMMA) on cY,-adrenergic responsiveness (phenylephrine 
1.25-8000 ng/ min) was studied after prolonged local venous infusion of TNF (8.7 pg in S h) in 9 volunteers and in 6 volunteers without 
previous cytokine exposure. Results: Mean (rt s.e.1 maximum phenylephrine constriction (E,) was 73 f 6% and log dose-rates 
exerting 50% of E,, (log ED,,) were 3.2 f 0.09 (geometric mean: 1535 ng/min). Local co-administration of L-NMMA at a dose 
sufficiently high to block NO formation (3.4 pmol/min) increased venous sensitivity to phenylephrine threefold (log ED,, 2.8 + 0.1, 
P < 0.015; geometric mean: 574 ng/min) whereas E,, was similar (73 + 5%). In the controls the phenylephrine dose-response 
relationship remained unaffected by simultaneous administration of L-NMMA. Conclusions: As no basal release of NO occurs in hand 
veins without previous exposure to TNF these results provide direct evidence for induction of NO formation in the human vasculature and 
consecutive resistance to a-adrenergic venoconstriction. NO might, therefore, he a key mediator of haemodynamic impairment in humans 
under conditions with known elevations of circulating TNF, such as a septic shock. 
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1. Introduction 
The haemodynamic characteristics of patients with sep- 
tic shock are consistent with the release of large amounts 
of vasodilator compounds resulting in a reduction of pe- 
ripheral vascular resistance and refractoriness to vasocon- 
strictors [l]. In vitro data and animal experiments suggest 
that endotoxin and endotoxin-induced release of inter- 
leukin-l/3 and tumour necrosis factor-a (TNF) are in- 
volved in the pathogenesis of generalised vasodilation 
12-61. A causal relationship is further supported by the 
similarity of haemodynamic changes observed after sys- 
temic infusion of TNF in humans [7,8]. There is good 
evidence that vascular smooth muscle cells release a va- 
sodilator after exposure to TNF [9] and that this vasodila- 
tor is most probably nitric oxide (NO) enzymatically 
formed from L-arginine by inducible NO synthase [lo]. 
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NO acts through the stimulation of soluble guanylate 
cyclase and subsequent formation of cyclic GMP which 
ultimately leads to relaxation of smooth muscle cells [ 111. 
In vivo administration of specific inhibitors of NO syn- 
thase [ 12- 141 or methylene blue, an inhibitor of NO-in- 
duced activation of guanylate cyclase [ 151, to patients with 
refractory septic shock has consistently increased systemic 
vascular resistance and blood pressure, suggesting that NO 
might be the cause. However, as NO is also released from 
arteries under basal conditions, L-NG-monomethyl-arginine 
(L-NMMA), a competitive, reversible inhibitor of NO 
synthesis [ 16-181, also exerts pressor responses in healthy 
subjects [19]. To data it has not been confiied that NO is 
released locally from the human vasculature after cytokine 
exposure in vivo. The results of these studies in superficial 
hand veins without basal NO release [20] confirm the 
vascular release of a vasodilator, which is most likely NO, 
in response to local TNF administration. 
Time for primary review 27 days. 
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2. Material and methods 
2.1. Subjects and protocol 
Fifteen healthy male non-smokers with a mean age of 
25 years (range 20-34 years) and a mean weight of 73 kg 
(63 to 84 kg) entered the study after giving written in- 
formed consent. No subject had a previous history of 
severe medical illness or used any chronic medication. 
Volunteers had not taken any medication within one week 
prior to the study. The current status of health was verified 
by a complete physical examination and routine laboratory 
tests. The volunteers were allowed to eat a light breakfast 
but were asked to refrain from methylxanthine-containing 
beverages and alcohol for at least 12 h before the study. 
The protocol was reviewed and approved by the local 
Ethical Committee; the investigation conforms with the 
principles outlined in the Declaration of Helsinki. 
2.2. Hand vein compliance technique 
The dorsal hand vein compliance technique [21] was 
used with modifications as previously described [22]. 
Briefly, a continuous infusion (0.25 ml/min) of normal 
saline was delivered through a 23 G needle into a suitable 
dorsal hand vein; a high precision infusion pump (Harvard 
Apparatus Inc., South Natick, MA, USA) was used at a 
constant delivery rate (0.25 ml/min). The arm was placed 
on a vacuum pillow above heart level sloping upwards at 
an angle of 30 degrees from the horizontal to allow for 
complete emptying of the vein. A tripod holding a linear 
variable differential transformer (Schaevitz Engineering, 
Pennsauken, NJ, USA) was mounted on the dorsum of the 
hand approximately 10 mm down-stream from the tip of 
the needle. The freely-movable core of the transformer was 
placed over the centre of the vein under investigation. The 
vertical movement of the core is directly proportional to 
the signal output of the transformer, which was recorded 
on a strip-chart recorder. The difference between the posi- 
tions of the core before and during inflation of a sphygmo- 
manometer cuff on the same arm to 40 mmHg gives a 
measure of the diameter changes under a given congestion 
pressure. Each phenylephrine dose was administered for at 
least 6 min to allow sufficient time for equilibration. The 
maximum constriction by phenylephrine was expressed as 
percentage change from baseline compliance which was 
set to 100%. Blood pressure, heart rate and axillary tem- 
perature were monitored on the opposite arm. Throughout 
the study the volunteers remained semirecumbent in a 
quiet room with a constant emperature of 23 f 1°C. 
2.3. Study design 
To study the potential release of vasodilator compounds 
induced by TNF, two dose-response curves to the CY,- 
adrenergic venoconstrictor phenylephrine were constructed 
in 9 volunteers in the absence and presence of L-NMMA, 
a competitive inhibitor of NO formation by NO synthase 
[23,24]. TNF (28.9 ng/min) in 0.5% human serum albu- 
min in normal saline was administered locally over 5 h 
into the vein under investigation (total dose: 8.7 pg/ 
experiment). The duration of TNF infusion was chosen 
according to in ,vitro studies in which it was shown that 
induction of NO synthase by TNF is dose-dependent and 
usually does not occur until several hours after exposure 
[25,26]. In two subjects, the infusion rate was higher (250 
ng/min) and the duration of TNF administration shorter 
(34 or 22 min) resulting in a total dose of 8.5 or 5.5 pg, 
respectively. After completion of the TNF infusion, the 
vein was kept patent by a continuous infusion of normal 
saline. Approximately 6 h after the beginning of TNF 
administration and after establishing a stable baseline, 
cumulative dose-rates of the full a,.selective agonist 
phenylephrine (1.25-8000 ng/ min) were administered lo- 
cally into the vein under investigation to construct a first 
dose-response curve. After a sufficiently long washout 
period (120 min) to negate the effect of phenylephrine, 
L-NMMA (3.4 ,umol/min) was infused for 20 min to 
allow the inhibitor to act. Then, while continuing adminis- 
tration of L-NMMA, a second dose-response curve to 
phenylephrine was constructed. The dose of L-NMMA in 
these experiments i in a range of its maximum inhibitory 
effect as established recently in hand vein experiments 
using bradykinin as a NO donor 1271. 
In a separate control group of 6 volunteers, the effect of 
the same L-NMMA dose on the phenylephrine dose-re- 
sponse curve was assessed without previous administration 
of TNF. 
2.4. Drugs 
L-NMMA was purchased from Clinalfa AG (Laufel- 
fingen, Switzerland) and phenylephrine (Neo-Synephrine” ) 
from Winthrop (Brussels, Belgium). TNF was a generous 
gift from Knoll AG (Ludwigshafen, Germany). To prevent 
TNF from sticking to tubing, 0.5% human serum albumin 
in normal saline was used as solvent. 
2.5. Data analysw 
Data are expressed as means + s.e. Indsvidual dose-re- 
sponse curves were fitted to a four-parameter logistic 
equation [28] by means of a computerised non-linear 
least-squares regression program (Allfit’, version 2.71, 
which provides estimates for the maximum effect (E,,,) 
and the dose-rate producing a half-maximal response 
(ED,,). Paired Student’s l-test was used to evaluate the 
difference between pairs of individual E,,,, and log ED,, 
values. The significance of the effect of I,-NMMA on 
ED,, values of mean phenylephrine dose-response curves 
was evaluated by F-test as previously described 1221. A 
two-tailed P value of less than 0.05 was considered to 
indicate statistical significance. 
3. Results 
In all 9 volunteers TNF was well tolerated. During the 
last hour of TNF administration a mild increase of temper- 
ature and heart rate, without effect on blood pressure 
values, was observed (Table 1). Occasionally, this was 
preceded by subjective symptoms of shivering and 
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Table 1 
Effects of TNF on body temperature and haemodynamics 
Before During Before phenyl- 
TNF TNF ephrine 
Temperature (“C) 36.4 (0.2) 37.7 (0.1) * * 37.2 (0.2) 
Systolic BP (mmHg) 112 (3) 112 (4) 114(4) 
Diastolic BP (mmHg) 69 (2) 70 (2) 69 (1) 
Heart rate (beats/min) 62 (2) 74(3) * 67 (3) 
* P < 0.05 vs baseline values before TNF. 
* * P < 0.01 vs baseline values before TNF. 
BP, blood pressure; all values are means ( f se.). 
headache. All symptoms were transient and resolved within 
one hour after the end of infusion, i.e. before the effects of 
phenylephrine were assessed. 
Pilot studies by our group in hand veins preconstricted 
with phenylephrine have shown that TNF, administered at 
dose rates up to 10 ng/min over 6 min, did not exert any 
immediate direct venodilator effects (data not shown). In 8 
of 9 volunteers phenylephrine constricted hand veins after 
pretreatment with TNF. Mean E,,, in these 8 volunteers 
was 73 + 6% and mean log ED,, was 3.2 f 0.09 (geomet- 
ric mean: 1535 ng/min). In one volunteer, doses of 
phenylephrine as high as 8000 ng/min did not constrict 
the hand vein at all. Blood pressure, heart rate and baseline 
venous compliance were unaffected by L-NMMA adminis- 
tration after 20 min (P > 0.2). Co-administration of 
phenylephrine with L-NMMA resulted in potent venocon- 
striction in all 9 volunteers including the subject who did 
not have a constrictor response previously. During L- 
NMMA E,,, values of these second phenylephrine 
dose-response curves were similar (73 f 5%; n.s.1 but 
mean log ED,, values were significantly lower, 2.8 + 0.1 
(geometric mean: 574 ng/min; P = 0.0151, suggesting 
that NO had shifted the dose-response curve towards 
higher dose-rates (Fig. 1). When only dose-response curves 
of the 6 volunteers were compared who had received TNF 
over 5 h, mean E,,, and log ED,, values were similar and 
the shift of the phenylephrine dose-response relationship 
was almost identical (geometric mean before and during 
L-NMMA: 1832 and 697 ng/min, respectively, P = 
0.033). 
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Fig. 1. Semilogarithmic plot of phenylephrine dose-response curves 
constructed 6-8 h after local exposure to TNF (8.7 pg) before (Cl) and 
during (A ) administration of L-NMMA in 8 healthy volunteers. 
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Fig. 2. Semilogarithmic plot of phenylephrine dose-response curves 
before (Cl) and during (A) administration of L-NMMA in 6 healthy 
volunteers constructed according to the same protocol as in Fig. 1 but 
without previous administration of TNF. 
The 6 volunteers in the L-NMMA control group did not 
differ with respect o age and weight from the group in 
which TNF was administered. The administration of L- 
NMMA before the second phenylephrine dose-response 
curve was again without any effect on baseline venous 
diameter (P = 0.19) and the second dose-response curve 
was not different from the curve constructed immediately 
before L-NMMA administration (Fig. 2). Mean E,,, val- 
ues before and during L-NMMA were 76 f 4% vs. 77 & 
5% (n.s.), respectively, and mean log ED,, values were 
2.8 + 0.1 (geometric mean: 638 ng/min) vs. 2.7 rt 0.2 
(geometric mean: 533 ng/ min), (P = 0.72), respectively. 
4. Discussion 
The cytokine TNF is an endogenous polypeptide pro- 
duced by macrophages and monocytes in response to 
exposure to endotoxin [11. Administered systemically, TNF 
induces many of the classic cardiovascular changes ob- 
served in septic shock [7] and there is good experimental 
evidence for the critical involvement of the L-arginine-NO 
pathway in hypotension and vascular hyporeactivity under 
these conditions [2,10,29]. TNF and other cytokines have 
been shown to promote the expression of the inducible 
isofotm of NO synthase in the vascular wall and to stimu- 
late synthesis and release of large amounts of NO [ 111. In 
line with the theory of causal participation of NO in septic 
shock, systemic administration of inhibitors of NO forma- 
tion (e.g. L-NMMA) has consistently increased blood pres- 
sure and peripheral vascular resistance in these patients 
[ 12-141. However, such findings only suggest but do not 
prove, the induction of NO synthase in humans, because 
the administration of L-NMMA or its analogues can also 
increase vascular tone and blood pressure in the absence of 
septicaemia [ 19,231. 
For two reasons, therefore, the dorsal hand vein compli- 
ance technique was deemed particularly useful to indi- 
rectly test the hypothesis that local administration of small 
amounts of TNF might result in the expression of the 
inducible isoform of NO synthase, and consecutively lead 
to the release of NO. First, this method allows the con- 
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struction of full dose-response curves in vivo without 
activation of cardiovascular reflexes. Second, the periph- 
eral veins are devoid of basal NO release [20]. Hence, the 
administration of inhibitors of NO synthase, or of forma- 
tion of its second messenger cGMP, does not modify basal 
venous compliance or affect the dose-response curve of 
cu-adrenoceptor agonists in native hand veins [20,22]. These 
previous findings are confirmed in this study by the lack of 
interaction of L-NMMA with the phenylephrine dose-re- 
sponse relationship under control conditions. As under 
optimal experimental conditions hand veins are devoid of 
significant tone, the local release of a venodilator will 
result in only minor changes of its congested diameter 
unless the vein is preconstricted with phenylephrine. This 
may explain why L-NMMA did not change baseline ve- 
nous diameter whereas it substantially shifted the dose-re- 
sponse relationship of phenylephrine. 
The results of the present study suggest hat exposure to 
locally elevated TNF levels may induce vascular hyposen- 
sitivity to cY-adrenergic constrictors while TNF was devoid 
of an acute vasodilator effect. Assuming local flow rates of 
2.5 ml/min 1301, local TNF concentrations were in a 
range similar to values reported in serum of patients with 
severe meningococcal septic shock [31]. In the present 
study, vascular responsiveness was markedly increased by 
co-administration of L-NMMA and, in accordance with 
previous studies in animals and humans, L-NMMA re- 
stored vascular responsiveness to adrenergic vasoconstric- 
tors [6,12- 14,321. Unlike other studies, however, these in 
vivo experiments assessed the effect of L-NMMA in a 
setting in which the inhibitor did not exert constrictor 
effects under basal conditions. Hence, it can be concluded 
that the potentiation of cr-adrenergic venoconstriction by 
L-NMMA reflects TNF-induced release of a local va- 
sodilator which is most likely NO formed by the cytokine- 
inducible isoform of NO synthase in smooth muscle cells. 
In addition to induction of NO release in vascular smooth 
muscle cells, TNF has also been reported to modulate NO 
release from the endothelium [33] and leukocytes [34], and 
to promote leukocyte adhesion to endothelial cells [35]. In 
addition to the well documented and quantitatively rele- 
vant NO release from smooth muscle cells, it appears 
therefore possible that also other cells within or adhering 
to the venous wall may have contributed to vasodilation 
induced by TNF in these experiments. 
In addition to its stimulatory effect on NO production, 
TNF was also shown to induce prostacyclin synthesis in 
cultured vascular endothelial cells [36] and to increase 
plasma 6-keto-PGF, (I in dogs [5]. As it was impossible to 
construct a third dose-response curve to phenylephrine 
while additionally blocking prostanoid effects in these 
long-lasting experiments, the eventual role of prostanoids 
remains open. However, the phenylephrine ED,, value 
obtained during L-NMMA administration after TNF infu- 
sion was quite similar to values previously reported in 
native hand veins [22] and to those measured in the 
absence of TNF in the control L-NMMA group. This 
suggests that a second vasodilator - if present at all - 
did not substantially modulate vascular sensitivity during 
the evaluated time period under these experimental condi- 
tions. 
Temporary changes in haemodynamic parameters and 
in axillary temperature have been observed during admin- 
istration of TNF in these studies. Mean heart rate and body 
temperature increased by 12 beats/min and 1.3”C, respec- 
tively, until discontinuation of TNF. These changes might 
reflect activation of the sympathetic nervous system as has 
been reported for other cytokines such as interleukin- 10 
(371. It is, however, unlikeIy that these changes have 
modified the response to phenylephrine and/or L-NMMA 
as both haemodynamic parameters and body temperature 
had returned to baseline values when dose--response curves 
to phenylephrine were constructed, 
The present study indicates that, within hours after TNF 
exposure, basal NO release also occurs m human capaci- 
tance vessels. Venous responsiveness was substantially 
impaired and it appears probable, tberefore, that part of the 
haemodynamic changes in septic shock occur at the ve- 
nous side of the circulation. As the subcutaneous venous 
vasculature contains a large fraction of the total blood 
volume, vasodilation in these vessels may further promote 
haemodynamic shock by venous pooling. Although this 
study provides support for the notion that NO is a key 
element in the pathogenesis of cytokine-associated vasodi- 
lation in humans, blockade of NO synthesis with L-NMMA 
may not be the optimal therapy. It has heen shown previ- 
ously that complete reversal of NO effects by high sys- 
temic doses of L-NMMA might be detrimental for recov- 
ery from a shock-like state as both constitutive and in- 
ducible isoforms of NO synthases are inhibited [29]. The 
development of NO synthase inhibitors [38] selective only 
for the inducible isozyme in the vascular wail would 
enable the treatment of septic shock states thereby elimi- 
nating the hyposensitivity to vasoconstrictors while pre- 
serving endothelial function. 
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